180 Life Sciences Corp.
For the period ended Jun 30, 2025. Filed Jul 23, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 23, 2025
FRMM$2.82-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
For The Three and Six Months Ended June 30, 2025 and 2024
| Accumulated · Total | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Stockholders’ | |||||||||||
| Series B Preferred · Common Stock · Treasury · Paid-in · Comprehensive · Accumulated · Equity | |||||||||||
| Shares · Amount · Shares · Amount · Stock · Capital · Income · Deficit · (Deficit) | |||||||||||
| Balance - January 1, 2025 | 1,000,000 | $100 | 3,176,999 | $318 | $ | - | $153,691,755 | $(2,916,918) | $(141,523,344) | $9,251,911 | |
| Cancelled shares | - | - | (2,385) | - | - | - | - | - | - | ||
| Shares issued for settlement of liabilities | - | - | 243,166 | 24 | - | 309,976 | - | - | 310,000 | ||
| Stock-based compensation | - | - | 450,000 | 45 | - | 577,539 | - | - | 577,584 | ||
| Conversion of Series B Convertible Preferred Stock | (1,000,000) | (100) | 1,318,000 | 132 | - | (32) | - | - | - | ||
| Comprehensive loss: | |||||||||||
| Net loss | - | - | - | - | - | - | - | (2,369,232) | (2,369,232) | ||
| Other comprehensive loss | - | - | - | - | - | - | (64,691) | - | (64,691) | ||
| Balance - March 31, 2025 | - | - | 5,185,780 | 519 | - | 154,579,238 | (2,981,609) | (143,892,576) | 7,705,572 | ||
| Shares issued for settlement of liabilities | - | - | 509,707 | 51 | - | 441,355 | - | - | 441,406 | ||
| Stock-based compensation | - | - | 343,721 | 34 | - | 103,590 | - | - | 103,624 | ||
| Commitment to repurchase common stock | - | - | - | - | (1,000,000) | - | - | - | (1,000,000) | ||
| Comprehensive loss: | |||||||||||
| Net loss | - | - | - | - | - | - | - | (1,726,604) | (1,726,604) | ||
| Other comprehensive loss | - | - | - | - | - | - | (143,435) | - | (143,435) | ||
| Balance - June 30, 2025 | - | $ | - | 6,039,208 | $604 | $(1,000,000) | $155,124,183 | $(3,125,044) | $(145,619,180) | $5,380,563 | |
| Balance - January 1, 2024 | - | $ | - | 534,719 | $54 | $ | - | $130,117,209 | $(2,901,339) | $(127,343,657) | (127,733) |
| Shares issued from exercise of August 2023 pre-funded warrants | - | - | 257,205 | 26 | - | 463 | - | - | 489 | ||
| Adjustment related to reverse stock split | - | - | 60,848 | 6 | - | (6) | - | - | - | ||
| Stock-based compensation | - | - | - | - | - | 236,062 | - | - | 236,062 | ||
| Comprehensive loss: | |||||||||||
| Net loss | - | - | - | - | - | - | - | (1,069,744) | (1,069,744) | ||
| Other comprehensive loss | - | - | - | - | - | - | 6,460 | - | 6,460 | ||
| Balance - March 31, 2024 | - | - | 852,772 | 86 | - | 130,353,728 | (2,894,879) | (128,413,401) | (954,466) | ||
| Shares issued for settlement of liabilities | - | - | 88,818 | 9 | - | 523,242 | - | - | 523,251 | ||
| Stock based compensation | - | - | - | - | - | 22,308 | - | - | 22,308 | ||
| Comprehensive income (loss): | - | - | |||||||||
| Net income | - | - | - | - | - | - | - | 11,781 | 11,781 | ||
| Other comprehensive income | - | - | - | - | - | - | (20,861) | - | (20,861) | ||
| Balance - June 30, 2024 | - | $ | - | 941,590 | $95 | $ | - | $130,899,278 | $(2,915,740) | $(128,401,620) | $(417,987) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.